Indeed, a causal role of IL-1β in NSCLC has been implicated from a phase III clinical trial showing that treatment with canakinumab, a human monoclonal antibody specific for IL-1β, reduced NSCLC incidence and lung cancer mortality in a dose-dependent manner (15). Here, IL1B is linked to non-small cell lung carcinoma.